Correlation of Circulating MMP-9 with White Blood Cell Count in Humans: Effect of Smoking

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Snitker, Soren ^a   Xie, Keming ^a,b   Ryan, Kathleen A ^a   Yu, Daozhan ^a   Shuldiner, Alan R ^a,c   Mitchell, Braxton D ^a   Gong, Da Wei ^a,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^c BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LEUKOCYTE COUNT; MALE; NEUTROPHIL COUNT; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SMOKING; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; SEX CHARACTERISTICS; SMOKING; YOUNG ADULT;

EID: 84879339314     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066277     Document Type: Article

References (57)

1. Back M, Ketelhuth DF, Agewall S, (2010) Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis 52: 410-428.
2. Lagente V, Boichot E, (2010) Role of matrix metalloproteinases in the inflammatory process of respiratory diseases. J Mol Cell Cardiol 48: 440-444.
3. Busti C, Falcinelli E, Momi S, Gresele P, (2010) Matrix metalloproteinases and peripheral arterial disease. Intern Emerg Med 5: 13-25.
4. Rydlova M, Holubec L Jr, Ludvikova M Jr, Kalfert D, Franekova J, et al. (2008) Biological activity and clinical implications of the matrix metalloproteinases. Anticancer Res 28: 1389-1397.
5. Jacob MP, (2003) Extracellular matrix remodeling and matrix metalloproteinases in the vascular wall during aging and in pathological conditions. Biomed Pharmacother 57: 195-202.
6. Arunachalam G, Sundar IK, Hwang JW, Yao H, Rahman I, (2010) Emphysema is associated with increased inflammation in lungs of atherosclerosis-prone mice by cigarette smoke: implications in comorbidities of COPD. J Inflamm (Lond) 7: 34.
7. Overbeek SA, Braber S, Koelink PJ, Henricks PAJ, Mortaz E, et al. (2013) Cigarette Smoke-Induced Collagen Destruction; Key to Chronic Neutrophilic Airway Inflammation? PLoS One 8: e55612.
8. Bauvois B, (2012) New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta 1825: 29-36.
9. Yang P, Yuan W, He J, Wang J, Yu L, et al. (2009) Overexpression of EphA2, MMP-9, and MVD-CD34 in hepatocellular carcinoma: Implications for tumor progression and prognosis. Hepatol Res 39: 1169-1177.
10. Kato R, Momiyama Y, Ohmori R, Taniguchi H, Nakamura H, et al. (2005) Levels of matrix metalloproteinase-1 in patients with and without coronary artery disease and relation to complex and noncomplex coronary plaques. Am J Cardiol 95: 90-92.
11. Hwang JJ, Yang WS, Chiang FT, Chen MF, Lin HJ, et al. (2009) Association of circulating matrix metalloproteinase-1, but not adiponectin, with advanced coronary artery disease. Atherosclerosis 204: 293-297.
12. Muzzio ML, Miksztowicz V, Brites F, Aguilar D, Repetto EM, et al. (2009) Metalloproteases 2 and 9, Lp-PLA(2) and lipoprotein profile in coronary patients. Arch Med Res 40: 48-53.
13. Welsh P, Whincup PH, Papacosta O, Wannamethee SG, Lennon L, et al. (2008) Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle-aged men. QJM 101: 785-791.
14. Dogan A, Tuzun N, Turker Y, Akcay S, Kaya S, et al. (2008) Matrix metalloproteinases and inflammatory markers in coronary artery ectasia: their relationship to severity of coronary artery ectasia. Coron Artery Dis 19: 559-563.
15. Zysset T, Polokoff MA, Simon FR, (1985) Effect of chronic ethanol administration on enzyme and lipid properties of liver plasma membranes in long and short sleep mice. Hepatology 5: 531-537.
16. Wu YW, Yang WS, Chen MF, Lee BC, Hung CS, et al. (2008) High serum level of matrix metalloproteinase-1 and its rapid surge after intervention in patients with significant carotid atherosclerosis. J Formos Med Assoc 107: 93-98.
17. Omachi TA, Eisner MD, Rames A, Markovtsova L, Blanc PD, (2011) Matrix metalloproteinase-9 predicts pulmonary status declines in alpha1-antitrypsin deficiency. Respir Res 12: 35.
18. Bolton CE, Stone MD, Edwards PH, Duckers JM, Evans WD, et al. (2009) Circulating matrix metalloproteinase-9 and osteoporosis in patients with chronic obstructive pulmonary disease. Chron Respir Dis 6: 81-87.
19. Brajer B, Batura-Gabryel H, Nowicka A, Kuznar-Kaminska B, Szczepanik A, (2008) Concentration of matrix metalloproteinase-9 in serum of patients with chronic obstructive pulmonary disease and a degree of airway obstruction and disease progression. J Physiol Pharmacol 59 Suppl 6: 145-152.
20. Koolwijk P, Miltenburg AM, van Erck MG, Oudshoorn M, Niedbala MJ, et al. (1995) Activated gelatinase-B (MMP-9) and urokinase-type plasminogen activator in synovial fluids of patients with arthritis. Correlation with clinical and experimental variables of inflammation. J Rheumatol 22: 385-393.
21. Gruber BL, Sorbi D, French DL, Marchese MJ, Nuovo GJ, et al. (1996) Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker. Clin Immunol Immunopathol 78: 161-171.
22. Giannelli G, Erriquez R, Iannone F, Marinosci F, Lapadula G, et al. (2004) MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in patients with rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol 22: 335-338.
23. Goncalves FM, Jacob-Ferreira AL, Gomes VA, Casella-Filho A, Chagas AC, et al. (2009) Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. Clin Chim Acta 403: 173-177.
24. Roberts CK, Won D, Pruthi S, Kurtovic S, Sindhu RK, et al. (2006) Effect of a short-term diet and exercise intervention on oxidative stress, inflammation, MMP-9, and monocyte chemotactic activity in men with metabolic syndrome factors. J Appl Physiol 100: 1657-1665.
25. Ramos-Fernandez M, Bellolio MF, Stead LG, (2011) Matrix metalloproteinase-9 as a marker for acute ischemic stroke: a systematic review. J Stroke Cerebrovasc Dis 20: 47-54.
26. Takagi H, Manabe H, Kawai N, Goto SN, Umemoto T, (2009) Circulating matrix metalloproteinase-9 concentrations and abdominal aortic aneurysm presence: a meta-analysis. Interact Cardiovasc Thorac Surg 9: 437-440.
27. Lim HS, Lip GY, (2008) Circulating matrix metalloproteinase-9 levels in atherosclerotic vascular disease: a possible measurement of systemic or specific disease pathophysiology? J Intern Med 263: 620-622.
28. Muroski ME, Roycik MD, Newcomer RG, Van den Steen PE, Opdenakker G, et al. (2008) Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr Pharm Biotechnol 9: 34-46.
29. Grodin JL, Powell-Wiley TM, Ayers CR, Kumar DS, Rohatgi A, et al. (2011) Circulating levels of matrix metalloproteinase-9 and abdominal aortic pathology: from the Dallas Heart Study. Vasc Med 16: 339-345.
30. Sands MF, (2012) Localization of matrix metalloproteinase (MMP)-9 in lung tissue of a murine model of allergic asthma. Immunol Invest 41: 87-96.
31. Jouneau S, Khorasani N, P DES, Macedo P, Zhu J, et al. (2011) EMMPRIN (CD147) regulation of MMP-9 in bronchial epithelial cells in COPD. Respirology 16: 705-712.
32. Batlle M, Perez-Villa F, Garcia-Pras E, Lazaro A, Orus J, et al. (2007) Down-regulation of matrix metalloproteinase-9 (MMP-9) expression in the myocardium of congestive heart failure patients. Transplant Proc 39: 2344-2346.
33. Li YY, Feng YQ, Kadokami T, McTiernan CF, Draviam R, et al. (2000) Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci U S A 97: 12746-12751.
34. Dziembowska M, Wlodarczyk J, (2012) MMP9: a novel function in synaptic plasticity. Int J Biochem Cell Biol 44: 709-713.
35. Bar-Or A, Nuttall RK, Duddy M, Alter A, Kim HJ, et al. (2003) Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain 126: 2738-2749.
36. Fang L, Du XJ, Gao XM, Dart AM, (2010) Activation of peripheral blood mononuclear cells and extracellular matrix and inflammatory gene profile in acute myocardial infarction. Clin Sci (Lond) 119: 175-183.
37. Genersch E, Hayess K, Neuenfeld Y, Haller H, (2000) Sustained ERK phosphorylation is necessary but not sufficient for MMP-9 regulation in endothelial cells: involvement of Ras-dependent and-independent pathways. J Cell Sci 113 Pt 23: 4319-4330.
38. Roomi MW, Monterrey JC, Kalinovsky T, Rath M, Niedzwiecki A, (2009) Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Oncol Rep 21: 1323-1333.
39. Chambaut-Guerin AM, Herigault S, Rouet-Benzineb P, Rouher C, Lafuma C, (2000) Induction of matrix metalloproteinase MMP-9 (92-kDa gelatinase) by retinoic acid in human neuroblastoma SKNBE cells: relevance to neuronal differentiation. J Neurochem 74: 508-517.
40. Li X, Zhao X, Ma S, (1999) Secretion of 92 kDa gelatinase (MMP-9) by bovine neutrophils. Vet Immunol Immunopathol 67: 247-258.
41. Kim KC, Lee CH, (2005) MAP kinase activation is required for the MMP-9 induction by TNF-stimulation. Arch Pharm Res 28: 1257-1262.
42. Ernens I, Rouy D, Velot E, Devaux Y, Wagner DR, (2006) Adenosine inhibits matrix metalloproteinase-9 secretion by neutrophils: implication of A2a receptor and cAMP/PKA/Ca2+ pathway. Circ Res 99: 590-597.
43. Pugin J, Widmer MC, Kossodo S, Liang CM, Preas HLn, et al. (1999) Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am J Respir Cell Mol Biol 20: 458-464.
44. Jonsson S, Lundberg A, Kalvegren H, Bergstrom I, Szymanowski A, et al. (2011) Increased levels of leukocyte-derived MMP-9 in patients with stable angina pectoris. PLoS One 6: e19340.
45. Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, et al. (2012) Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 7: e37483.
46. Velthove KJ, Bracke M, Souverein PC, Schweizer RC, Ten Berg MJ, et al. (2009) Identification of exacerbations in obstructive lung disease through biomarkers. Biomarkers 14: 523-528.
47. Odagiri K, Uehara A, Mizuta I, Yamamoto M, Kurata C, (2011) Longitudinal study on white blood cell count and the incidence of metabolic syndrome. Intern Med 50: 2491-2498.
48. Oda E, Kawai R, (2009) The prevalence of metabolic syndrome and diabetes increases through the quartiles of white blood cell count in Japanese men and women. Intern Med 48: 1127-1134.
49. Mitchell BD, McArdle PF, Shen H, Rampersaud E, Pollin TI, et al. (2008) The genetic response to short-term interventions affecting cardiovascular function: rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study. Am Heart J 155: 823-828.
50. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, et al. (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. Jama 302: 849-857.
51. Hansson J, Lind L, Hulthe J, Sundstrom J, (2009) Relations of serum MMP-9 and TIMP-1 levels to left ventricular measures and cardiovascular risk factors: a population-based study. Eur J Cardiovasc Prev Rehabil 16: 297-303.
52. Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, et al. (2004) Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 109: 2850-2856.
53. Garvin P, Nilsson L, Carstensen J, Jonasson L, Kristenson M, (2008) Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle-aged normal population. PLoS One 3: e1774.
54. Vu TH, Werb Z, (2000) Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 14: 2123-2133.
55. Brew K, Dinakarpandian D, Nagase H, (2000) Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477: 267-283.
56. Avolio C, Ruggieri M, Giuliani F, Liuzzi GM, Leante R, et al. (2003) Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol 136: 46-53.
57. Hansson J, Vasan RS, Ärnlöv J, Ingelsson E, Lind L, et al. (2011) Biomarkers of Extracellular Matrix Metabolism (MMP-9 and TIMP-1) and Risk of Stroke, Myocardial Infarction, and Cause-Specific Mortality: Cohort Study. PLoS One 6: e16185.